Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer

被引:2
|
作者
Gannichida, Ako [1 ]
Nakazawa, Yusuke [1 ,3 ]
Kageyama, Akira [1 ]
Utsumi, Hirofumi [2 ]
Kuwano, Kazuyoshi [2 ]
Kawakubo, Takashi [1 ]
机构
[1] Jikei Univ Hosp, Dept Pharm, Tokyo 1058471, Japan
[2] Jikei Univ, Dept Internal Med, Div Resp Dis, Sch Med, Tokyo 1058461, Japan
[3] Jikei Univ Hosp, Dept Pharm, 3-19-18 Nishi Shimbashi,Minato Ku, Tokyo 1058471, Japan
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 13卷 / 07期
关键词
Nivolumab; Hypothyroidism; Immune checkpoint inhibitors; Immune-related adverse event; Neutrophil-to-lymphocyte ratio; ADVERSE EVENTS; OPEN-LABEL; TREATED PATIENTS; CELL; OUTCOMES; CHEMOTHERAPY; ASSOCIATION; MULTICENTER; TRIALS;
D O I
10.5306/wjco.v13.i7.641
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Low neutrophil-to-lymphocyte ratio (NLR) has been shown to be associated with a favorable therapeutic response to nivolumab. The activation of immunocompetent cells such as lymphocytes exhibits an antitumor effect; however, the development of excessive immune responses in autologous organs along with the breakdown of self-tolerance causes immune-related adverse events, including hypothyroidism. Therefore, the possibility that NLR is associated with immune response shows that NLR can be not only a predictive factor for good response to nivolumab but also a predictive factor for the development of hypothyroidism. AIM To evaluate whether continuous NLR monitoring during nivolumab treatment is useful for predicting the incidence and onset period of hypothyroidism. METHODS This retrospective study comprised patients who received nivolumab for treating all types of cancer at our hospital between January 2015 and December 2019. The NLRs of patients were measured before each administration, and the patients were followed up till the administration of 12 doses. NLR at treatment initiation was compared between patients with and without hypothyroidism. Patients who developed hypothyroidism were categorized into three groups: those with NLR < 3.5, 3.5 to < 5, and >= 5 according to their maximum NLR from treatment initiation to hypothyroidism development. Further, the onset periods of hypothyroidism were compared between the groups. RESULTS Overall, 104 patients were included in the analysis. Twenty-one patients developed hypothyroidism throughout the observation period. NLR at treatment initiation was significantly lower (2.54 & PLUSMN; 1.21 vs 4.58 & PLUSMN; 4.03; P = 0.017) in patients with hypothyroidism than in those without hypothyroidism, and patients with NLR < 5 had a significantly higher incidence of hypothyroidism than those with NLR & GE; 5 (26%: 20 of 78 patients vs 4%: 1 of 26 patients; P = 0.022). Additionally, treatment continuity in patients with hypothyroidism was significantly longer than in those without hypothyroidism (median not reached vs 7 times administration, P = 0.010). Patients with maximum NLR < 3.5 until the development of hypothyroidism had a significantly earlier onset of hypothyroidism than those with maximum NLR & GE; 5 (hazard ratio for low tertile [NLR < 3.5] vs high tertile [NLR & GE; 5]: 5.33, P = 0.011). CONCLUSION Low NLR at treatment initiation increases the incidence of treatment-induced hypothyroidism. Furthermore, its persistence may be a risk factor for the early onset of hypothyroidism.
引用
收藏
页码:641 / 651
页数:11
相关论文
共 50 条
  • [1] Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy
    Yamada, Takanobu
    Hayashi, Tsutomu
    Inokuchi, Yasuhiro
    Hayashi, Kimihiro
    Watanabe, Hayato
    Komori, Keisuke
    Kano, Kazuki
    Shimoda, Yota
    Fujikawa, Hirohito
    Shiozawa, Manabu
    Morinaga, Soichiro
    Rino, Yasushi
    Masuda, Munetaka
    Ogata, Takashi
    Oshima, Takashi
    [J]. TARGETED ONCOLOGY, 2020, 15 (03) : 317 - 325
  • [2] Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab
    Shibata, E.
    Yokoi, T.
    Takahashi, R.
    Mikami, K.
    Kanemura, S.
    Koda, Y.
    Negi, Y.
    Fujimoto, E.
    Akano, Y.
    Tada, A.
    Minami, T.
    Kuribayashi, K.
    Kijima, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S708 - S708
  • [3] Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy
    Takanobu Yamada
    Tsutomu Hayashi
    Yasuhiro Inokuchi
    Kimihiro Hayashi
    Hayato Watanabe
    Keisuke Komori
    Kazuki Kano
    Yota Shimoda
    Hirohito Fujikawa
    Manabu Shiozawa
    Soichiro Morinaga
    Yasushi Rino
    Munetaka Masuda
    Takashi Ogata
    Takashi Oshima
    [J]. Targeted Oncology, 2020, 15 : 317 - 325
  • [4] Prognosis and Neutrophil-to-Lymphocyte Ratio in Nivolumab-treated Patients with Recurrent/Metastatic Head and Neck Cancer
    Ota, I.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1174 - 1174
  • [5] Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
    Su, Meng-Xia
    Lin, Hsiang-Wen
    Nguyen, Hanh T. H.
    Lin, Tien-Chao
    Chen, Chih-Jung
    Wang, Hwei-Chung
    Wu, Chen-Teng
    Wu, Yao-Chung
    He, Geng-Yan
    Liu, Liang-Chih
    Huang, Chih-Hao
    [J]. BMC CANCER, 2024, 24 (01)
  • [6] Neutrophil-to-Lymphocyte Ratio in Patients With Cirrhosis
    Bakshi, Satvinder Singh
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (04) : 799 - 799
  • [7] Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
    Meng-Xia Su
    Hsiang-Wen Lin
    Hanh T. H. Nguyen
    Tien-Chao Lin
    Chih-Jung Chen
    Hwei-Chung Wang
    Chen-Teng Wu
    Yao-Chung Wu
    Geng-Yan He
    Liang-Chih Liu
    Chih-Hao Huang
    [J]. BMC Cancer, 24
  • [8] Neutrophil-to-lymphocyte ratio in trauma patients
    Park, Joon Min
    [J]. JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2017, 82 (01): : 225 - 226
  • [9] Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival
    Ota, Yumiko
    Takahari, Daisuke
    Suzuki, Takeshi
    Osumi, Hiroki
    Nakayama, Izuma
    Oki, Akira
    Wakatsuki, Takeru
    Ichimura, Takashi
    Ogura, Mariko
    Shinozaki, Eiji
    Suenaga, Mitsukuni
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (02) : 265 - 272
  • [10] Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival
    Yumiko Ota
    Daisuke Takahari
    Takeshi Suzuki
    Hiroki Osumi
    Izuma Nakayama
    Akira Oki
    Takeru Wakatsuki
    Takashi Ichimura
    Mariko Ogura
    Eiji Shinozaki
    Mitsukuni Suenaga
    Keisho Chin
    Kensei Yamaguchi
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 85 : 265 - 272